Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › savolitinib

savolitinib

2 published articles · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Case report on sequential therapy for MET exon 14 skipping NSCLC with high PD-L1
Oncology Meta-analysis
Case report on sequential therapy for MET exon 14 skipping NSCLC with high PD-L1 A New Drug Sequence Shrank Lung Tumors When Others Failed
This is a case report with literature review of a 79-year-old male with MET exon 14 skipping non-small cell lung cancer and high PD-L1 expre…
A 79-year-old man's lung tumors shrank when doctors switched his drug sequence, offering a clue for others with hard-to-treat cancer.
Frontiers May 12, 2026
Savolitinib and durvalumab combination yields response rates of 34% to 53% in papillary renal cancer patients
Oncology Phase II
Savolitinib and durvalumab combination yields response rates of 34% to 53% in papillary renal cancer patients New Hope for a Tough Kidney Cancer Type
This single-arm phase II study evaluated savolitinib and durvalumab in 41 treatment-naïve or pretreated patients with papillary renal cancer…
A new drug pair breaks the shield blocking treatment for a rare kidney cancer type, offering patients a chance at longer survival after stan…
Apr 20, 2026